Department of Periodontics, Government Dental College and Research Institute, Bangalore, Karnataka, India.
Department of Orthodontics, Government Dental College and Research Institute.
J Periodontol. 2017 Oct;88(10):1023-1029. doi: 10.1902/jop.2017.150096. Epub 2017 Jul 21.
The aim of this study is to investigate efficacy of metformin (MF) 1% gel as an adjunct to scaling and root planing (SRP) in the treatment of moderate and severe chronic periodontitis (CP).
Seventy patients were categorized into two treatment groups: 1) SRP plus 1% MF and 2) SRP plus placebo. Clinical parameters were recorded at baseline and 3, 6, and 9 months. They included plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), and clinical attachment level (CAL). Radiologic assessment of intrabony defects (IBDs) and percentage defect depth reduction (DDR%) was done at baseline and 6- and 9-month intervals using computer-aided software. PD, CAL, and DDR% were evaluated in two subgroups in both the placebo and MF group: 1) initial PD of 5 to 7 mm and 2) initial PD of >7 mm.
Mean PD reduction and mean CAL gain was found to be greater in the MF group than the placebo group at all visits. Clinical parameters (PD, CAL) in both subgroups, with initial PDs of 5 to 7 and >7 mm, showed significant improvement in the 1% MF group compared with the placebo group. A significantly greater mean DDR% was found in the MF group than the placebo group at 6 and 9 months in both subgroups, 5 to 7 and >7 mm of initial PD.
There was a greater decrease in PD and more CAL gain with significant IBD depth reduction at sites treated with SRP plus locally delivered MF in patients with CP in both initial PD = 5 to 7 and >7 mm subgroups compared with placebo.
本研究旨在探讨二甲双胍(MF)1%凝胶作为辅助刮治和根面平整(SRP)治疗中重度慢性牙周炎(CP)的疗效。
70 名患者分为两组治疗:1)SRP 加 1% MF,2)SRP 加安慰剂。基线和 3、6 和 9 个月记录临床参数。包括菌斑指数(PI)、改良龈沟出血指数(mSBI)、探诊深度(PD)和临床附着水平(CAL)。使用计算机辅助软件在基线和 6 个月和 9 个月间隔评估骨内缺损(IBD)和百分比缺损深度减少(DDR%)。在安慰剂和 MF 组的两个亚组中评估 PD、CAL 和 DDR%:1)初始 PD 为 5 至 7mm,2)初始 PD >7mm。
MF 组的平均 PD 减少和平均 CAL 增加均大于安慰剂组,所有时间点均如此。在初始 PD 为 5 至 7mm 和 >7mm 的两个亚组中,所有临床参数(PD、CAL)均显示 MF 组较安慰剂组有显著改善。在初始 PD 为 5 至 7mm 和 >7mm 的两个亚组中,MF 组的平均 DDR%均显著高于安慰剂组,分别在 6 个月和 9 个月时。
在初始 PD 为 5 至 7mm 和 >7mm 的两个亚组中,与安慰剂相比,SRP 加局部给予 MF 治疗的 CP 患者,PD 下降更大,CAL 获得更多,IBD 深度显著减少。